GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Labcorp Holdings Inc (FRA:N6B) » Definitions » EV-to-EBITDA

Labcorp Holdings (FRA:N6B) EV-to-EBITDA : 16.46 (As of May. 23, 2024)


View and export this data going back to 1991. Start your Free Trial

What is Labcorp Holdings EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Labcorp Holdings's enterprise value is €21,031 Mil. Labcorp Holdings's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was €1,278 Mil. Therefore, Labcorp Holdings's EV-to-EBITDA for today is 16.46.

The historical rank and industry rank for Labcorp Holdings's EV-to-EBITDA or its related term are showing as below:

FRA:N6B' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.78   Med: 10.3   Max: 18.4
Current: 16.55

During the past 13 years, the highest EV-to-EBITDA of Labcorp Holdings was 18.40. The lowest was 5.78. And the median was 10.30.

FRA:N6B's EV-to-EBITDA is ranked better than
50% of 112 companies
in the Medical Diagnostics & Research industry
Industry Median: 16.625 vs FRA:N6B: 16.55

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-23), Labcorp Holdings's stock price is €187.64. Labcorp Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €4.603. Therefore, Labcorp Holdings's PE Ratio for today is 40.76.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Labcorp Holdings EV-to-EBITDA Historical Data

The historical data trend for Labcorp Holdings's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Labcorp Holdings EV-to-EBITDA Chart

Labcorp Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.87 7.37 8.16 12.16 18.21

Labcorp Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.04 14.64 15.26 18.21 17.62

Competitive Comparison of Labcorp Holdings's EV-to-EBITDA

For the Diagnostics & Research subindustry, Labcorp Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Labcorp Holdings's EV-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Labcorp Holdings's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Labcorp Holdings's EV-to-EBITDA falls into.



Labcorp Holdings EV-to-EBITDA Calculation

Labcorp Holdings's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=21030.922/1277.582
=16.46

Labcorp Holdings's current Enterprise Value is €21,031 Mil.
Labcorp Holdings's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €1,278 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Labcorp Holdings  (FRA:N6B) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Labcorp Holdings's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=187.64/4.603
=40.76

Labcorp Holdings's share price for today is €187.64.
Labcorp Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €4.603.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Labcorp Holdings EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Labcorp Holdings's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Labcorp Holdings (FRA:N6B) Business Description

Traded in Other Exchanges
Address
358 South Main Street, Burlington, NC, USA, 27215
Laboratory Corp. of America is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.

Labcorp Holdings (FRA:N6B) Headlines

No Headlines